CURRICULUM VITAE - Mario Negri · CURRICULUM VITAE Personal data Name : Gianluigi Forloni Date and...
34
1 CURRICULUM VITAE Personal data Name : Gianluigi Forloni Date and place of birth: May 15,1956 in Rho (Mi), Italy Citizenship: Italian Residence: Piazza San Vittore , 7, 20017 Rho (Mi) Education 1976 Diploma in Industrial Chemistry, Rho (Mi) 1985 Degree in Biological Sciences, University of Milan Research Experience 1977-1980 Technician fellow, Laboratory of Neuropharmacology of the Cholinergic System, Mario Negri Institute of Pharmacological Research, Milan. 1980-1985 Senior technician, Laboratory of Neuropharmacology of the Cholinergic System, Mario Negri Institute 1986-1988 Postdoctoral fellow, Department of Psychiatry and Neuroscience, The Johns Hopkins University, School of Medicine, Baltimore, U.S.A. 1988-1992 Research assistant,Laboratory of Geriatric Neuropsychiatry Mario Negri Institute 1992 -1995 Head of the Unit of Neurobiology of Alzheimer, Mario Negri Institute. 1996 - present Head of the Laboratory of Biology of Neurodegenerative Disorders, Mario Negri Institute. 2002- present Head of the Department of Neuroscience, Mario Negri Institute. Area of research :
Transcript of CURRICULUM VITAE - Mario Negri · CURRICULUM VITAE Personal data Name : Gianluigi Forloni Date and...
1
CURRICULUM VITAE
Personal data Name : Gianluigi Forloni Date and place of birth: May 15,1956 in Rho (Mi), Italy Citizenship: Italian Residence: Piazza San Vittore , 7, 20017 Rho (Mi)
Education
1976 Diploma in Industrial Chemistry, Rho (Mi)
1985 Degree in Biological Sciences, University of Milan
Research Experience
1977-1980 Technician fellow, Laboratory of Neuropharmacology of the Cholinergic
System, Mario Negri Institute of Pharmacological Research, Milan.
1980-1985 Senior technician, Laboratory of Neuropharmacology of the Cholinergic
System, Mario Negri Institute
1986-1988 Postdoctoral fellow, Department of Psychiatry and Neuroscience, The
Johns Hopkins University, School of Medicine, Baltimore, U.S.A.
1988-1992 Research assistant,Laboratory of Geriatric Neuropsychiatry Mario Negri
Institute
1992 -1995 Head of the Unit of Neurobiology of Alzheimer, Mario Negri Institute.
1996 - present Head of the Laboratory of Biology of Neurodegenerative Disorders,
Mario Negri Institute.
2002- present Head of the Department of Neuroscience, Mario Negri Institute.
Area of research:
2
Biological and genetic bases of Alzheimer’s disease (AD), Prion-related encephalopathies (PRE) and Parkinson's disease (PD). Studies on pathogenesis and possible therapeutic approaches based on the role of protein aggregation in the neurodegenerative diseases and mechanisms of neuronal death using in vitro and in vivo models. Identification of biological markers of disease.
Membership :
American Society of Neuroscience, 1987-
Italian Association Research on Brain Aging, 1989- (1999- member of Directive
Council, 2003- President)
New York Accademy of Science, 1992-96
Italian Society of Neuroscience, 2000-
European Academy of Science, 2004-
International Society to Advance Alzheimer Research and Treatment (ISTAART)
2008-
Brain Mapping and Therapeutics 2014-
Scientific Committees Membership
Scientific Committee of Dementia section (SINDEM) of Italian Society of
Neurology
Scientific Committee of the Trial Stamina appointed by Italian Ministry of Health
Scientific Committee "Associazione per la Ricerca sulle Demenze", Association
for the Research on the Dementia
Editorial Board:
Biochemical Journal 2000-2007
Brain Aging 2003-2010
Journal Epigenetics of Neurodegenerative Diseases
Open Geriatric Medicine Journal
Open Longevity Science
PlosOne (Academic Editor)
International Journal of Molecular Epidemiology
3
Dr. Forloni has served as a member of several committees of the European
Community for the examination of the projects in the Neuroscience field. He is now
member of the Coordinating Group of the European Consortium “IMI-PharmaCog”. He
has been in charge of an elective course on genetic of neurodegenerative disorders at
the Medical School of the University of Milan, he was invited for lectures and seminars
in numerous Universities and Research Centers. Dr. Forloni is the author of more than
250 peer-review scientific articles and about 30 reviews or book chapters, H index=54
(google scholar). Bibliography Articles 1979 1. Consolo S., Forloni G., Garattini S., Ladinsky H., Tirelli A.S. Differential effects of the isomers of fenfluramine and norfenfluramine on rat striatal
acetylcholine content. J. Pharm. Pharmacol. 31: 706 (1979) 1980 2. Consolo S., Ladinsky H., Forloni G., Tirelli A.S., Garattini S. Comparison of the effects of the stereoisomers of fenfluramine on the acetylcholine
content in rat striatum, hippocampus an nucleus accumbens. J. Pharm. Pharmacol. 32: 201-203 (1980) 3. Ladinsky H., Consolo S., Tirelli A.S., Forloni G. Evidence for noradrenergic mediation of the oxotremorine-induced increase in
acetylcholine content in rat hippocampus. Brain Res. 187: 494-498 (1980) 1981 4. Ladinsky H., Consolo S., Forloni G., Tirelli A.S. Studies on the indirect feedback inhibition of cholinergic neurons triggered by
oxotremorine in striatum. Brain Res. 225: 217-223 (1981) 1982 5. Consolo S., Ladinsky H., Forloni G., Grombi P. Modulation of the hippocampal alpha-adrenoceptor population by lesion of the
serotonergic raphe-hippocampal pathway in rats.
4
Life Sci. 30: 1113-1120 (1982) 1983 6. Forloni G., Consolo S., Grombi P., Wang J.X., Mennini T., Ladinsky H. Modifications in recognition sites for neurotransmitters in rat hippocampus by
kainic acid lesion. Brain Res. 274: 165-170 (1983) 7. Consolo S., Forloni G., Fisone G., Sieklucka M., Ladinsky H. Mediation by the corticostriatal input of the in vivo increase in rat striatal acetylcholine
content induced by 2-chloroadenosine. Biochem. Pharmacol. 32: 2993-2996 (1983) 1984 8. Garattini S., Forloni G., Tirelli A.S., Ladinsky H., Consolo S. Neurochemical effects of minaprine, a novel psychotropic drug on thecentral
cholinergic system of the rat. Psychopharmacology (Berl.) 82: 210-214 (1984) 9. Consolo S., Wang J.X., Fusi R., Vinci R., Forloni G., Ladinsky H. In vitro and in vivo evidence for the existence of presynaptic muscarinic cholinergic
receptors in the rat hippocampus. Brain Res. 309: 147-151 (1984) 1985 10. Consolo S., Wang J.X., Forloni G., Mocchetti I., Racagni G., Ladinsky H. Studies on the up regulation of alpha-adrenoceptors on rat hippocampal perikarya by
chemical lesion of the median raphe nucleus. Life Sci. 37: 449-460 (1985) 11. Wang J.X., Consolo S., Vinci R., Forloni G., Ladinsky H. Characterization of the alpha adrenergic receptor population in hippocampus up
regulated by serotonergic raphe deafferentiation. Life Sci. 36: 255-270 (1985) 12. Kolasa K., Consolo S., Forloni G., Garattini S., Ladinsky H. Blockade of the diazepam-induced increase in rat striatal acetylcholine content by
the specific benzodiazepine antagonists ethyl-beta-carboline-3-carboxylate and Ro 15-1788.
Brain Res. 336: 342-345 (1985) 1986 13. Consolo S., Sieklucka M., Fiorentini F., Forloni G., Ladinsky H. Frontal decortication and adaptive changes in striatal cholinergic neurons in the rat. Brain Res. 363: 128-134 (1986)
5
14. Forloni G., Fisone G., Consolo S., Ladinsky H. Qualitative differences in the effects of adenosine analogs on the cholinergic
systems of rat striatum and hippocampus. Naunyn Schmiedebergs Arch. Pharmacol. 334: 86-91 (1986) 15. Forloni G., Fisone G., Guaitani A., Ladinsky H., Consolo S. Role of the hippocampus in the sex-dependent regulation of eating behavior: Studies with kainic acid. Physiol. Behav. 38: 321- 326 (1986) 1987 16. Forloni G., Bidzinski A., Fusi R., Ladinsky H., Consolo S. Striatal cholinergic function reflects differences in D-2 dopaminergic receptor
activation. Life Sci. 41: 1717-1723 (1987) 17. Forloni G.L, Graznna, R. Blakely R., and Coyle J.T. Co-localization of N-acetyl-aspartyl-glutamate in cholinergic, noradrenergic and
serotonergic neurons Synapse, 1, 455-460 (1987) 18. Saltarelli M.D., Forloni G., Oster-Granite M.L., Gearhart J.D., Coyle J.T. Neurochemical characterization of embryonic brain development in trisomy 19 (Ts19)
mice: Implications of selective deficits observed for abnormal neural development in aneuploidy.
Dev. Genet. 8: 267-279 (1987) 1988 19. Guarda A., Robinson M., Ory-Lavollee L., Forloni G.,Blakely R. and Coyle J.T. Quantitation of N-acetyl-aspartyl-glutamate in microdissected rat brain nuclei and
peripheral tissue: findings with anovel liquid phase radioimmunoassay Molec.Brain Research 3: 223-232 (1988) 20. Consolo S., Forloni G., Ladinsky H. and Palazzi E. Frontal decortication enhances opiate catalepsy in rats. Brain Res. 449: 97-103 (1988) 21. Bendotti C., Forloni G., Morgan R., Reeves R., Oster-Granite M.,Gerheart J. and Coyle
J.T. Neuroanatomical localization and quantification of amyloid precursor protein mRNA by in situ hybridization in the brains of normal, aneuploid and lesioned mice
Proc.Nat.Acad.Sci (USA) 85: 3628-3632 (1988) 22. Tsai, G.,Forloni G., Robinson, M.B., Stauch, B.L. and Coyle, J.T. Calcium-dependent evoked release of [3H]N-acetylaspartylglutamate from the
optic pathway J. Neurochem. 51: 1956-195 (1988)
6
1989 23. Stauch L.B., Robinson M.B., Forloni G., Tsai G. and Coyle J.T. The effects of N-Acetylated Alpha-Linked Acidic Dipeptidase (NAALADase)
inhibitors on [3H]NAAG catabolism in vivo Neurosci Lett.100: 90-95 (1989) 24. Forloni G., Blake K, Hohmann C.H. and Coyle J.T. The postnatal expression of acetylcholinesterase in somatostatin-positive cells of
mouse hippocampus Dev. Brain Research 48: 73-85 (1989) 1990 25. Frondoza C., Logan S., Forloni G. and Coyle, J.T. Production and characterization of monoclonal antibodies to N-acetyl-aspartyl-glutamate J.Histochem Cytochem.38, 493-502 (1990) 26. Forloni G., Hohmann C., Coyle J.T. Developmental expression of somatostatin in mouse brain. I. Immunocy-
tochemical studies. Dev. Brain Res. 53: 6-25 (1990) 27. Bendotti C., Hohmann C., Forloni G., Reeves R.H., Coyle J.T., Oster-Granite M.L. Developmental expression of somatostatin in mouse brain. II. In situ hybridization. Dev. Brain Res. 53: 26-39 (1990) 29. Consolo S., Bertorelli R., Forloni G., Butcher L.L. Cholinergic neurons of the pontomesencephalic tegmentum release acetylcholine
in the basal nuclear complex of freely moving rats. Neuroscience 37: 717-723 (1990) 30. Cella S.G., Locatelli V., Mennini T., Zanini A., Bendotti C., Forloni G., Fumagalli G., Arce
V., De Gennaro C.V., Wehrenberg W.B., Muller E.E. Deprivation of growth hormone-releasing hormone early in the rat's neonatal life
permanently affects the somatotropic function. Endocrinology 127: 1625-1634 (1990) 31. Bendotti C., Servadio A., Forloni G., Angeretti N., Samanin R. Increased tryptophan hydroxylase mRNA in raphe serotonergic neurons spared by
5,7-dihydroxytryptamine. Mol. Brain Res. 8: 343-348 (1990) 32. Forloni G., Angeretti N., Amoroso D., Addis A., Consolo S. Decrease in [3H]hemicholinium binding to high-affinity choline uptake sites in
deafferented striatum: Restoration by oxiracetam. Brain Res. 530: 156-160 (1990)
7
33. Rosina A., Morara S., Provini L., Forloni G. Modulation of cerebellar CGRP binding sites induced by climbing fibre activation. NeuroReport 1: 215-217 (1990) 1991 34. Vezzani A., Forloni G., Serafini R., Rizzi M., Samanin R. Neurodegenerative effects induced by chronic infusion of quinolinic acid in rat striatum
and hippocampus. Europ.J. Neurosci. 3: 40-46 (1991) 35. Manfridi A., Forloni G., Vezzani A., Fodritto F., De Simoni M.G. Functional and histological consequences of quinolinic and kainic acid-induced
seizures on hippocampal somatostatin neurons. Neuroscience 41: 127-135 (1991) 36. Bertorelli R., Forloni G., Consolo S. Modulation of cortical in vivo acetylcholine release by the basal nuclear complex: Role
of pontomesencephalic tegmental area. Brain Res. 563: 353-356 (1991) 37. Spagnoli A., Lucca U., Menasce G., Bandera L., Cizza G., Forloni G., Tettamanti M.,
Frattura L., Tiraboschi P., Comelli M., Senin U., et al. Long-term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology 41: 1726-1732 (1991) 1992 38 Forloni G., Angeretti N., Rizzi M., Vezzani A. Chronic infusion of quinolinic acid in rat striatum: Effects on discrete neuronal
populations. J. Neurol. Sci. 108: 129-136 (1992) 39. Forloni G., Angeretti N. Decreased [3H]hemicholinium binding to high-affinity choline uptake sites in aged rat
brain Brain Res. 570: 354-357 (1992) 40. Han S.Y., Sweeney J.E., Bachman E.S., Schweiger E.J., Forloni G., Coyle J.T., Davis
B.M., Joullie` M.M. Chemical and pharmacological characterization of galanthamine, an acetylcholinesterase inhibitor, and its derivatives. A potential
application in Alzheimer's disease?. Europ. J.Med.Chem. 27: 673-687 (1992) 41. Giorgi S., Forloni G., Amoroso D., Consolo S. Expression of GAL mRNA in rat
hypothalamus: Effect of frontal deafferentation and colchicine treatment. Mol. Brain Res. 14: 277-281 (1992) 42. Provini, L., Morara, S., Rosina, A. and Forloni, G., Expression of CGRP binding sites in
the developing rat cerebellum, Ann. N. Y. Acad. Sci., 657:423-425 (1992).
8
43 Rosina, A., Morara, S., Provini, L. and Forloni, G., Activation of olivocerebellar fibers induces an increase in CGRP cerebellar binding sites, Ann. N. Y. Acad. Sci., 657: 432-434 (1992)
44. Forloni G., Demicheli F., Giorgi S., Bendotti C., Angeretti N. Expression of amyloid
precursor protein mRNAs in endothelial, neuronal and glial cells: Modulation by interleukin-1. Mol. Brain Res. 16: 128-134 (1992)
45. Manfridi A., Forloni G., Arrigoni-Martelli E., Mancia M. Culture of dorsal root ganglion
neurons from aged rats: Effects of acetyl-l-carnitine and NGF. Int. J. Dev. Neurosci. 10: 321-329 (1992) 1993 46. Masseroli M., Bollea A., Bendotti C., Forloni G. In situ hybridization histochemistry
quantification: Automatic count on single cell in digital image. J. Neurosci. Methods 47: 93-103 (1993). 47. Forloni G., Angeretti N., Chiesa R., Monzani E., Salmona M., Bugiani O.,Tagliavini F. Neurotoxicity of a prion protein fragment. Nature 362: 543-546 (1993). 48. Forloni G., Chiesa R., Smiroldo S., Verga L., Salmona M., Tagliavini F., Angeretti N. Apoptosis mediated neurotoxicity induced by chronic application of beta amyloid
fragment 25-35. NeuroReport 4: 523-526 (1993) 49. Ammassari-Teule M., Amoroso D., Forloni G., Rossi-Arnaud C., Consolo S. Mechanical deafferentation of basal forebrain-cortical pathways and neurotoxic
lesions of the nucleus basalis magnocellularis: Comparative effect on spatial learning and acetylcholine release in vivo.
Behav. Brain Res. 54: 145-152 (1993) 50. Forloni G., Del Bo R., Angeretti N., Smiroldo S., Gabellini N., Vantini G. Nerve growth factor does not influence the expression of beta amyloid precursor
protein mRNA in rat brain: In vivo and in vitro studies. Brain Res. 620: 292-296 (1993) 51. Selvaggini C., De Gioia L., Cantu' L., Ghibaudi E., Diomede L., Passerini F., Forloni G., Bugiani O., Tagliavini F., Salmona M. Molecular characteristics of a protease-resistant, amyloidogenic and neurotoxic peptide homologous to residues 106-126 of the prion protein. Bioch. Biophy. Res. Comm. 194: 1380-1386 (1993) 52. Tagliavini F., Prelli F., Verga L., Giaccone G., Sarma R., Gorevic P., Ghetti B., Passerini
F., Ghibaudi E., Forloni G., Salmona M.,Bugiani O. and Frangione, B. Synthetic peptides homologous to prion protein residues 106-147 form amyloid-like fibrils in vitro. Proc. Natl. Acad. Sci. (USA) 90: 9678- 9682 (1993) 53. Masseroli, M., Messori, A. Ponti, M., Bendotti C., Forloni G.
9
Automatic quantitatiive evaluation of autoradiographic band films by computerized image analysis
LIfe Sciences 53: 331- 336 (1993) 54. Masseroli M., Bollea A., Forloni G. Quantitative morphology and shape
classification of neurons by computerized image analysis. Comput. Meth. Progr. Biomed. 41: 89- 99 (1993) 1994 55. Forloni G., Angeretti N., Smiroldo S. Neuroprotective activity of acetyl-L-carnitine: studies in vitro. J. Neurosci. Res. 37: 92-96 (1994) 56. De Gioia L.Selvaggini C, Ghibaudi E., Diomede L., Forloni G., Bugiani O., Tagliavini F.,
Salmona M. Conformational polymorphism of the amyloidogenic and neurotoxic peptide homologous
to residues 106-126 of the prion protein J. Biol. Chem. 269: 7859-7862 (1994) 57. Forloni, G., Del Bo, R., Angeretti, N. Smiroldo, Chiesa, R., Doni R. Ghibaudi E.
Salmona, M., Porro, M., Verga, L. Giaccone, G. Bugiani, O., Tagliavini, F. A neurotoxic prion protein fragment induces rat astroglial proliferation in vitro. Eur. J. Neurosci. 6:1415-1422 (1994) 58. Lucca, U., Tettemanti, M., Forloni, G. and Spagnoli A. Nonsteroidal anti-inflammatory drug use in Alzheimer's disease and elderly
population. Biol. Psychiatry 36: 854- 856 (1994) 1995 69 Del Bo R., Angeretti, N., Lucca E. De Simoni M.G. and Forloni, G. Reciprocal control of inflammatory cytokines and � amyloid production in cultures Neurosci lett. 188: 70-74 (1995) 60. De Simoni, M.G., Del Bo R., De Luigi A., Simard, S. and Forloni, G. Central endotoxin induces different patterns of IL 1� and IL 6 secretion in the brain and
periphery Endocrinology 136: 897-802 (1995) 61 Giorgi, S. Forloni; G. Baldi, G. Consolo, S. Expression and release of galanin in rat hypothlamus during postnatal development Eur. J. Neurosci. 7: 944-950 (1995) 62. Porzio, S., Masseroli, M., Messori, A., Forloni, G., Olivetti, G. Jeremic,G. Luvara, G..
Riva, E. Latini, R. A simple, automatic method for morphometric analysis of the left ventricle in rats with myocardial infarction
J. Pharmacol. Toxicol. Methods 33: 221-229 (1995)
10
1996 63. Cafè, C. Torri, C., Bertorelli, L., Angeretti, N., Lucca, E., Forloni, G. and Marzatico, F.
Oxidative stress after acute and chronic application of ��amyloid fragment 25-35 in cortical coltures.
Neurosci. Lett. 203: 61- 65 (1996) 64. Chiesa, R., Angeretti, N., Lucca, E., Salmona, M., Tagliavini, F., Bugiani, O. Forloni, G.
Clusterin (SGP-2) induction in rat astroglial cells exposed to prion protein fragment 106-126”
Eur. J. Neurosci. 8: 589-597 (1996) 65. Scorziello, A., Meucci, O., Florio, T., Grimaldi, M., Fattore, Galli, C., Forloni, G.,
Salmona, M. and Schettini, G. ß 25-35 alters calcium homeostasis and induces neurotoxicity in cerebellar granular cells
J. Neurochem. 66: 1995-2003 (1996) 66. Forloni, G. Bugiani, O., Tagliavini, F. and Salmona M. Apoptosis mediated neurotoxicity induced by �-amyloid and PrP fragments Molec. and Chem. Neuropathol. 28: 163-171 (1996) 67. Forloni, G., Tagliavini, F.,Bugiani, O. and Salmona, M. Amyloid in Alzheimer’s disease and prion-related encephalopathies: Studies with
synthetic peptides Progr. Neurobiol. 49: 287- 315 (1996) 68. Florio, T. Grimaldi, M., Scorziello, A., Salmona, M., Bugiani, O.,Tagliavini, F. Forloni, G.
and Schettini G. Intracellular calcium rise through L-type calcium channels, as molecular mechanism for
prion protein fragment 106-126-induced astroglial proliferation Bioch. Biophys. Res. Comm. 228: 397-405 (1996) 69. Diomede, L., Sozzani, S., Luini, W., Algeri, M.,Chiesa, R., De Gioia L. Lievens, P.M.J.,
Bugiani, O. Tagliavini, F., Forloni, G. and Salmona, M. Activation effects of prion protein fragment [PrP (106-126)] on human leucocytes Biochem. J. 320, 563-570 (1996) 70. Forloni, G. Neurotoxicity of amyloid and prion peptides Curr.Op. Neurol. 9, 492-500 (1996) 1997 71. Forloni, G. Lucca, E., Angeretti, N., Chiesa, R. and Vezzani A. Neuroprotective effect of somatostatin on non-apoptotic NMDA-induced neuronal death:
role of cGMP J. Neurochem. 68: 319- 327 (1997) 72. Rizzardini, M., Chiesa R., Lucca, E. Angeretti, N., Salmona, M., Forloni, G.and Cantoni,
L.
11
Prion protein fragment 106-126 differentially induces heme hoxygenase-1 mRNA in cultured neurons and astroglial cells
J. Neurochem. 68: 715-720 (1997) 73. Tagliavini, F., McArthur, R.A., Canciani, B., Giaccone, G., Porro, M.,Bugiani, O., Lievens,
M-J., Bugiani, O. Peri, E., Dall'ara, P., Rocchi, M., Poli, G.,Forloni, G., Bandera, T., Varasi, M., Suarato, A., Cassuti, P., Cervini, MA., Lansen, J.,Salmona, M. Post, C. Effectiveness of anthracycline against experimental prion disease in syrian hamsters
Science, 276: 1119-1122 (1997) 74. Salmona, M.,Forloni, G., Diomede, L., Algeri, M., De Gioia, L. Angeretti, N. Giaccone, G.
Tagliavini, F. and Bugiani, O. A neurotoxic and gliotrophic fragment of the prion protein increases plasma membrane
microviscosity. Neurobiol. Diseases 4: 47- 57 (1997) 75. Lucca, E., Angeretti, N., Forloni, G. Influence of cell culture conditions on the protective effect of antioxidants against
��amyloid toxicity: studies with lazaroids. Brain Res. 764: 923- 928 (1997) 76. Forloni, G., Lucca, E., Angeretti, N., Della Torre, P. and Salmona, M. Amidation of amyloid peptide strongly reduced the amyloidogenic activity without
alteration of the neurotoxicity J. Neurochem. 69: 2048-2054 (1997) 77. Forloni, G., Mangiarotti, F., Angeretti, N., Lucca E. and De Simoni, MG. Amyloid fragment potentiates IL-6 and TNF� secretion by LPS in astrocytes but not in microglia Cytokine 9: 759- 762 (1997) 78. Andreoni, G., Angeretti, N., Lucca, E. and Forloni, G. Densitometric quantification of cell viability by computerized image analysis Experim. Neurology 148: 281-287 (1997) 79. De Simoni, MG., Terreni, L., Chiesa, R., Mangiarotti, F. and Forloni, G. Interferon � and TNF�, but not IL-1� induced by endotoxin in the brain Endocrinology 538, 5220-5226 (1997) 1998 80. Chiesa,R., Angeretti, N., Del Bo, R., Lucca, E., Munna, E. and Forloni, G. Extracellular calcium deprivation in astrocytes: regulation of mRNA expression and
apoptosis J. Neurochem.70, 1474-1483, (1998) 81. Corsi,P, Forloni, G, Troia, M. Lettini, T. Coyle J.T. Somatostatin expression in ts16 mouse brain cultures. J. Mol . Neurosci. 10, 99-111 (1998)
12
82. Florio, T., Thellung, S., Amico, C., Robello,M., Salmona, M., Bugiani, O.,Tagliavini, F. Forloni, G. and Schettini G.
The prion protein fragment 106-126 induces apoptotic cell death and impairment of intracellular calcium homeostasis in the GH3 cell line
J. Neurosci. Res. 54, 341-352 (1998) 1999 83. Forloni, G., Angeretti,N., Malesani, P., Peressini,E., Rodriguez Martin, T., Della Torre,
P.,Salmona,M. Influence of mutations associated with familial prion-related encephalopathies on biological effects of PrP peptides
Ann. Neurol. 45: 489-94 (1999) 84 Salmona, M., Malesani, P., De Gioia, L., Molinari, A., Della Vedova, F. Pedrotti, B.,
Marrari, M.A. Bugiani, O,Forloni, G. and Tagliavini, F. Molecular determinants of the chemico-physical properties of a critical region comprising the residues 106-126 Biochem J 342: 207-214 (1999)
85 Ragg, E. Malesani, P., Monticelli, L. Bugiani, O., Tagliavini, F., Forloni, G., Salmona, M.
Determination of solution conformations of PrP 106-126, a neurotoxic fragment of prion protein, by H NMR and restrained molecular dynamics Eur J Biochem. 266:1192-1201 (1999) 2000 86. Forloni, G., Salmona, M. Bugiani O. and Tagliavini, F. Comment on: Neurotoxicity of
prion peptide 106-126 not confirmed by Beat Kunz, Erika Sandmeier, Philip Christen, FEBS Letters 458 (1999) 65-68
FEBS Letters 466: 205-206 (2000) 87. Galbete JL., Rodriguez Martin, T., Peressini, E., Modena, P. Bianchi, R.
Forloni, G. Cholesterol reduces APPs by interfering with glycosylation in the protein secretory pathway Biochem. J. 348: 307-313 (2000)
88. Forloni, G., Bertani, I. Calella, AM., Thaler, F.Invernizzi. R. Alpha-synuclein and Parkinson's disease: selective neurodegeneration effect of alpha-synuclein fragment on dopaminergic neurons in vitro.
Ann. Neurol. 47: 632-640 (2000) 89. Thellung S, Florio T, Corsaro A, Arena S, Merlino M, Salmona M, Tagliavini F, Bugiani O,
Forloni G, Schettini G. Intracellular mechanisms mediating the neuronal death and astrogliosis induced by the prion protein fragment 106-126.
Int J Dev Neurosci. 18:481-492 (2000) 90. Borghi, R., Marchese, R. Negro, A. Marinelli, L., Forloni, G. Zaccheo D. Tabaton, M. Full length -synuclein is present in cerebrospinal fluid from Parkinson’s disease and
normal subjects. Neurosci Lett 287 :65-67 (2000).
13
91. Tagliavini F, Forloni G, Colombo L, Rossi G, Girola L, Canciani B, Angeretti N, Giampaolo L, Peressini E, Awan T, De Gioia L, Ragg E, Bugiani O, Salmona M.
Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J Mol Biol. 300:1309-22 (2000) 92. Thellung S, Florio T, Villa V, Corsaro A, Arena S, Amico C, Robello M, Salmona M,
Forloni G, Bugiani O, Tagliavini F, Schettini G. Apoptotic Cell Death and Impairment of L-Type Voltage-Sensitive Calcium Channel Activity in Rat Cerebellar Granule Cells Treated with the Prion Protein Fragment 106-126. Neurobiol Dis. 7: 299-309 (2000).
93. Rodriguez Martin T., Calella AM., Silva S., Munna E., Modena, P., Chiesa,R., Terrevazzi,
S., Ruggieri R.M., Palermo R., Piccoli, F., Confalonieri R., Tiraboschi, P., Fragiacomo, C., Quadri, P., Lucca U. and Forloni G. ApoE and polymorphism of presenilin-1 and �1-antichymotrypsin in Alzheimer and vascular dementia. Dementia Geriat Cognit. Dis. 11: 239-244 (2000)
94. Morara, S., Rosina, A., Provini, L., Forloni, G. Caretti, A. Wimalawansa,S. CGRP receptor expression in neurons and glia of the developing rat cerebellum: an autoradiographis and immunohistochemical analysis
Neuroscience 14: 100:381-391 (2000) 95. Sáez-Valero, J., Angeretti, N. Forloni, G. Caspase-3 activation by ��-amyloid and Prion
protein peptides is independent from their neurotoxic effect Neurosci. Lett. 293: 207-210 (2000)
2001
96. Forloni, G., Colombo, L., Gerola, L., Tagliavini, F. and Salmona, M. Anti-amyloidogenic activity of tetracyclines FEBS letters 487:404-407 (2001) 97. Terreni, L., Calabrese, E. Calella, A.M., Forloni, G. Mariani,C.
New mutation (R42P) of the parkin gene in the ubiquitin-like domain associated with Parkinsonism Neurology ;56:463-466 (2001)
98. Caramelli M, Ru G, Casalone C, Bozzetta E, Acutis PL, Calella A, Forloni G. Evidence for the transmission of scrapie to sheep and goats from a vaccine against Mycoplasma agalactiae. Vet Rec. 2001 Apr 28;148(17):531-6.
99. Tagliavini, F., Forloni, G., D'ursi, P., Bugiani, O. and Salmona M. Studies on peptide fragments of PrP Adv Protein Chem. 57:171-201 (2001) 2002 100. Bonetto, V., Massignan, T., Chiesa, R., Morbin, M., Mazzoleni, G., Diomede, L.,
Angeretti, N., Colombo, L., Forloni, G., Tagliavini, F. and Salmona M. Syntheric Miniprion PrP106 J. Biol. Chem. 277: 31327-31334 (2002)
14
101. Forloni G. Iussich, S. Awan T. Colombo L.Angeretti, N. Girola, L. Bertani, I. Poli, G.
Caramelli, M. Bruzzone, MG.Farina, L. Limido, L. Rossi, G. Giaccone G. Ironside, JW. Bugiani, O.Salmona M. and Tagliavini, F. Tetracyclines affect prion infectivity
Proc. Natl. Acad. Sci . New York 99: 10849-10854 (2002) 102. Diomede, L., Forloni, G., Bugiani, O.,Tagliavini F.and Salmona. M. The prion protein and
cellular cholesterol homeostasis. Neurobiology of Lipids Vol.1, 3 2003; 1: 8-14 (2002) 103. Forloni G.,Terreni L., Bertani, I., Fogliarino S., Assini A., Ribizzi G., Negro A., Calabrese
E., Volontè MA., Mariani C. Franceschi M., Tabaton M., Invernizzi R. and Bertoli A.
Protein misfolding in Alzheimer's and Parkinson's disease: genetics and molecular mechanisms, Neurobiol Aging 23, 957-976 (2002)
2003 104. Assini, A. Terreni, L. Borghi, R., Giliberto, L., Piccini, A., Loqui, D. Fogliarino, S. Forloni,
G. and Tabaton, M. Pure spastic paraparesis associated with a novel presenilin-1 R278K mutation. Neurology 60: 150-151 (2003)
105. Zanusso, G., Casalone, C. Acutis, P., Bozzetta, E., Farinazzo, A., Gelati, M., Fiorini, M. Forloni, G., Sun Sy, M., Monaco, S. and Caramelli M. Molecular analysis of iatrogenic scrapie in Italy. J. Gen. Virology 84: 1047-1052 (2003)
106. Soriano FX., Galbete JL. and Forloni, G.Effect of � amyloid on endothelial cell lack of
direct toxicity, enhancement of MTT-induced cell death and intracellular accumulation. Neurochem International 43: 251-261 (2003)
107. Forloni, G., Varì, MR., Colombo, L., Bugiani, O., Tagliavini, F. and Salmona, M. Prion
diseases: Time for a Therapy ? Current Med Chem-Immun., Endoc, & Metab. Agents, 3, 185-197 (2003)
108. Rossi G, Salmona M, Forloni G, Bugiani O, Tagliavini F. Therapeutic approaches to prion
diseases. Clin Lab Med. 23:187-208 (2003) 109. Terreni, L. Fogliarino, S. Quadri, PL., Lucca , U. and Forloni, G. Tumor necrosis factor
��polymorphism C-850T is not associated with Alzheimer's Disease and vascular dementia in an Italian population. Neurosci Lett 344: 135-137 (2003)
110. Bahadi R, Farrelly PV, Kenna BL, Kourie JI, Tagliavini F, Forloni G, Salmona
M.Channels formed with a mutant prion protein PrP(82-146) homologous to a 7-kDa fragment in diseased brain of GSS patients. Am J Physiol Cell Physiol. 285: C862-72 (2003)
111. Barret, A., Tagliavini, F., Forloni, G., Salmona M., Colombo, L., De Luigi A., Limido, L.
Suardi S., Rossi G. Auvré, F., Adjou, K.T , Salès, N., Bate, C., Williams, A., Lasmézas
C. Deslys J.P. Evaluation of quinacrine treatment for prion diseases. J. Virology 77: 8462-8469 (2003)
15
112. Confaloni., A., Terreni L., Piscopo P., Crestini A., Malvezzi Campeggi I. Sala Frigerio C., Blotta I., Perri M., Di Natale M., Maletta R.,Marcon G., Bruni AC., Forloni, G. Cantafora A. Nicastrin gene in familial and sporadic alheimer’s disease. Neurosci Lett 253:61-65 (2003)
113. Salmona, M., Morbin, M., Massignan, T., Colombo, L., Mazzoleni, L., Capobianco L. ,
Diomede, L., Thaler, F., Mollica L., Musco, G., Kourie JJ., Bugiani, O., Sharma D., Inouye, H., Kirschner, DA., Forloni G. Tagliavini F. Structural properties of Gerstmann-Sträussler-Scheinker disease amyloid protein J. Bbiol. Chem. 278::48146-53 (2003).
114. Farrelly, PV., Kenna, BL.,Laohachai, KL.,Bahadi, R., Salmona, M., Forloni, G. Kourie, JI.
Quinacrine blocks PrP(106-126)-formed channels. J. Neurosci Res. 74:934-41 (2003) 2004 115. Biasini, E., Fioriti, L., Ceglia, I., Bertoli, A. Invernizzi, R., Chiesa, R. , Forloni,
G.Proteasome inhibition and aggregation in Parkinson's disease: fart and artifacts in cellular models. J. Neurochem. 88:545-53. (2004)
116 . Quadri P, Fragiacomo C, Pezzati R, Zanda E, Forloni G, Tettamanti M, Lucca U.
Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. Am J Clin Nutr. 80:114-22 (2004)
117. Fenoglio C. , Galimberti, D., Lovati, C. Guidi, I. , Gatti, A., Fogliarino, S., Tiriticco, M.,
Mariani, C. Forloni, G. Pettinati, C., Baron, P., Conti, G. Bresolin, N. and Scarpini, E. MCP-1 in Alzheimer’s disease patients: A-2518G polymorphism and serum levels
Neurobiology of Aging 25: 1169-73. (2004) 118. Albani D., Peverelli, E., Zametta, R., Veschini, L. Negro, A. Forloni G. Protective effect of
TAT-delivered alpha synuclein: relevance of the C-terminal domain and involvement of HSP70. FASEB J. 18:1713-5 (2004)
119. Galimberti, D., Fenoglio, C., Lovati, C., Gatti, A., Guidi, I. Ventanelli, E., Gary, R.,
Mariani, C., Forloni, G. Pettenati, C., Baron, P. Comi, G. Bresolin, N. and Scarpini, E. CCR2-641 plymorphism and CCR5D32 deletion in patients with Alzheimer’s disease
J. Neurol Sci 225: 79-83 (2004) 120. Forloni G., Immune system contributing to prion diseaseas, Drug Discovery Today: Disease mechanisms 1: 351-356 (2004) 2005 121. Fioriti, L. Quaglio, E., Harris, D., Forloni G., Chiesa, R. The neurotoxicity of prion protein
(PrP) peptide 106-126 is independent of the expression level of PrP and is not mediated by abnormal PrP species. Mol. Cell Neurosci. 28:165-176 (2005)
16
122. Fioriti, L. Quaglio, E., Stewart, LR., Stewart, RS., Harris, D., Forloni G., Chiesa, R Cytosolic prion protein (PrP) is not toxic in N2a cells and primari neurons expressing pathogenic PrP mutations J. Biol. Chem 280: 11320-11328 (2005)
123. Guidi I., Galimberti D., Venturelli E., Lovati C., Del Bo R., Fenoglio C., Gatti A., Dominici
R., Galbiati S., Virgilio R., Pomati S., Comi G.P., Mariani C., Forloni G., Bresolin N., Scarpini E., Influente of the GLU298Asp polymorphism of NOS3 on age at onset and homocysteine levels in AD patients, Neurobiol Aging 26: 789-794 (2005)
124. Confaloni A, Crestini A , Terreni L., Piscopo P. , Malvezzi Campeggi L. , Fogliarino S. ,
Tartaglia M.and Forloni G. Rat nicastrin gene: cDNA isolation, mRNA variants and expression pattern analysis. Mol. Brain Res 136: 12-22 (2005)
125. Venturelli E, Galimberti D, Lovati C, Fenoglio C, Scalabrini D, Mariani C, Forloni G,
Bresolin N, Scarpini E. The T-786C NOS3 polymorphism in Alzheimer's disease: Association and influence on gene expression. Neurosci Lett. 2005 382: 300-3. (2005)
126. Salmona, M., Capobianco, R., Colombo, L., De Luigi A., Rossi, G. Mangieri, M.,
Giaccone, G., Quaglio, E, Chiesa, R. Donati, MB., Tagliavini, F. and Forloni G. Role of plasminogen in propagation of scrapie. J. Virol. 79: 11225-11230 (2005)
127. Sala Frigerio. C. Piscopo, P. Calabrese, E., Crestini, A., Malvezzi Campeggi, L., Civita di
Fava, R. Fogliarino, S., Albanii, D., Marcon, G., Cherchi, R.Piras,, R. Forloni,, G., Confaloni A. PEN-2 mutation associated with Alzheimer’s disease,. J. Neurol. 252: 1033-6 (2005)
128. Galimberti, D. , Venturelli, E Gatti, A., Lovati, C., Fenoglio C., Mariani, C. Forloni, G.,
Bresolin, N. Scarpini, E. Association of neuronal nitriic oxide synthase C276T polymorphism with Alzheimer's disease. J. Neurol 252: 985-6 (2005)
129. Cervo, L. Canetta, A., Calcagno, E., Burbassi, S., Sacchetti, G., Caccia, S., Fracasso, C.,
Albani, D., Forloni, G. Invernizzi, RW. Genotype-dependent activity of tryptophan hydroxylase-2 determines the response to citalopran in a mouse model of depression. J. Neurosci. 25: 8165-72 (2005)
2006 130. Gobbi, M.Colombo L., Morbin, M., Mazzoleni, G., Accordo, E., Vanoni, M., Del Favero,
E., Cantù L. . Kirschner, DA., Canzoni, C., Ceci, P., Ubezio, P., Forloni, G., Tagliavini, F., Salmona, M. Gerstmann-Sträussler-Scheinker disease amyloid protein polymerizes according to the “dock-and-lock “ model. J. Biol. Chem. 281: 843-9 (2006)
131. Caramelli, M. Acutis, G., Ru, G., Forloni, G. Prion Diseases: current understanding and
research CNS Drugs 20: 15-28.(2006) 132. Acutis, PL, A. Bossers, J. Priem, M.V. Riina, S. Peletto, M. Mazza, C. Casalone, G.
Forloni, G. Ru, M. Caramelli. Identification of prion protein gene polymorphisms in goats from Italia scrapie outbreaks J. Gen Virol., 87: 1029-1033 (2006)
133. Ricchelli, F., Buggio, R., Drago, D., Salmona, M., Forloni G., Negro A., Tognon,
G., Zatta P. Aggregation/fibrillogenesis of recombinant human prion protein and
17
gerstmann-sträussler-scheinker disease peptides in the presence of metal ions. Biochemistry, 45: 6724-32 (2006)
134. Biasini, E., V. Rossi, Massignan T., Fioriti, L., Harris, D. Forloni, G. Bonetto, V. Chiesa,
R. Proteomic analysis of a transgenic mouse model of inherited prion disease reveals preclinical alteration of calcineurin activity. Proteomics. 6: 2823-34 (2006)
135. Pesaresi, M. Lovati, c. Bertora, P., Mailland, E., Galimberti, D., Scarpini, E. Quadri, P.,
Forloni, G. Mariani, C. Plasma levels of beta-amyloid (1-42) in Alzheimer and mild cognitive impairment Neurobiol Aging 27: 904-905 (2006 )
136. Rastaldi, MP. Armelloni, S., Berra S., Calvaresi, N., Corbelli, A., Giardino LA., Li,
m., Pesaresi, M. Wang, GQ., Fornasieri, A., Villa, A., Heikkila E., Soliymani, R., Boucherot, A., Cohen, CD., Kretzler, M., Nitsche, M., Koller, KP, Malgaroli, A., Forloni, G., Schlöndorff, D., Holthofer, H. D’Amico, G.. Glomerular podocytes contain neuron-like functional synaptic vesicles. FASEB J. 20: 976-8 (2006)
137. Venturelli E, Galimberti D, Fenoglio C, Lovati C, Finazzi D, Guidi I, Corra B, Scalabrini
D, Clerici F, Mariani C, Forloni G, Bresolin N, Scarpini E. Candidate gene analysis of IP-10 gene in patients with Alzheimer's disease.
Neurosci Lett. 404: 217-21 (2006) 138. Bauer M, Langer O, Dal-Bianco P, Karch R, Brunner M, Abrahim A, Lanzenberger
R, Hofmann A, Joukhadar C, Carminati P, Ghirardi O, Piovesan P, Forloni G, Corrado ME, Lods N, Dudczak R, Auff E, Kletter K, Muller M. A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease. Clin Pharmacol Ther. 80: 216-27. (2006)
139. Serretti, A., Liappas, J, Mandelli, L., Albani D., Forloni, G., Malitas, P., Piperi, C.,
Zisaki, A., Tzavellas EO., Papadopoulou-Daifoti, Z., Prato, F., Batelli, S., Pesaresi, M., Kalofoutis, A. Interleukin-1 alpha and beta, TNF-alpha and HTTLPR gene variants study on alcohol toxicity and detoxification outcome. Neurosci Lett 406: 107-12 (2006)
2007 140. Fenoglio C, Galimberti D, Piccio L, Scalabrini D, Panina P, Buonsanti C, Venturelli
E, Lovati C, Forloni G, Mariani C, Bresolin N, Scarpini E. Absence of TREM2 polymorphisms in patients with Alzheimer's disease and Frontotemporal Lobar Degeneration. Neurosci Lett. 411:133-7 (2007)
141. Fioriti, L. Angeretti, N.. Colombo, L., De Luigi A., Manzoni, C., Colombo A.,
Morbin, M., Tagliavini, F., Salmona, M. Chiesa, R. Forloni, G. Neurotoxic and gliotrophic activity of a synthetic peptide homologous to Gerstmann-Sträussler-Scheinker disease amyloid protein. J. Neurosci. 27: 576-83 (2007)
142. Gallucci M., Amici, GP. OngaroF. Gajo G.B., De Angeli, S. Forloni G., Albani, D.
Prato F. Polito , L. Zanardo A and Regini C. Associations of the plasma interleukin 6 (il-6) levels with disability and mortality in the elderly in the treviso longeva (trelong) study. Arch Geriatr. Geront. 44 Suppl: 193-8. (2007)
18
143. Gallucci M.,. Ongaro F. Bresolin F. Bernardi, U. Salvato, C. Minello A., Amici, GP.,
Barasciutti, E., Mazzucco, S., Gajo G.B, De Angeli, S. Forloni G., Albani, L. Zanardo A and Regini C. The treviso longeva (trelong) study: a biomedical, demographic, economic and social investigation on people 70 years and over in a typical town of north-east of italy. Arch Geriat Geront 44 Suppl:173-92. (2007)
144. Pesaresi M, Batelli S, Prato F, Polito L, Lovati C, Scarpini E, Quadri P, Mariani C,
Albani D, Forloni G. The urokinase-type plasminogen activator polymorphism PLAU_1 is a risk factor for APOE-epsilon4 non-carriers in the Italian Alzheimer's disease population and does not affect the plasma A beta(1-42) level.
Neurobiol Dis. 25: 609-613 (2007)
145. Albani D., Batelli, S., Pesaresi, M. Prato, F., Polito L. Forloni G. Pantieri R. A novel PSENEN mutation in a MCI patient with positive family history for Alzheimer’s Disease. Alzheimer & Dementia 3: 235-238 (2007)
146. Albani, D., Artuso V. Roiter, I. Batelli, S., Prato, F. Pesaresi, M. Galimberti, D. Scarpini,
E., Bruni, A., Franceschi, M. Piras MR., Confaloni, A. and Forloni G. Presenilin-1 mutation E318G represents a risk factor for familial Alzheimer’s disease in the Italian population and affects A�(1-40) production Neurobiol Aging. 28:1682-8 (2007)
147. Borsello, T. Forloni, G. JNK signaling: a target to prevent neurodegeneration.
Current Pharmaceutical Design. 13: 875-886 (2007) 148. Colombo, A., Repici M., Pesaresi M. Santambrogio S. Forloni G. and Borsello T. The
Amyloid Precursor Protein processing is regulated by JNK phosporylation in the cytoplasmic domain: D-JNKI1 inhibits its proteolytic cleavage
Cell Death Differ.14:1845-8 (2007) 149. Repici M, Centeno C, Tomasi S, Forloni G, Bonny C, Vercelli A, Borsello T. Time-
course of c-Jun N-terminal kinase activation after cerebral ischemia and effect of D-JNKI1 on c-Jun and caspase-3 activation. Neuroscience. 150:40-9 (2007)
2008 150. De Luigi A, Colombo L, Diomede L, Capobianco R, Mangieri M, Miccolo C, Limido
L, Forloni G, Tagliavini F, Salmona M. The efficacy of tetracyclines in peripheral and intracerebral prion infection PLoS ONE. 2008 Mar 26;3(3): e1888
151. Batelli, S., Rametta R., Polito, L., Prato, F., Albani, D., Forloni, G.DJ-1 protects SK-
N-BE neuroblastoma cells from oxidative stress and modulates TAT-delivered synuclein protective function: relevance for Parkinson’s disease and involvement of HSP70. PLoS ONE. 2008 Apr 2;3(4):e1884.
152. Batelli, S., Albani, D., Prato, F., Polito, L., Franceschi, M. Gavazzi, A., Forloni, G.
Early Onset Alzheimer’s Disease in an Italian family with presenilin-1 double mutation E318G and G394V, Alzheimer Dis Assoc Disord. 22: 184-7, 2008
19
153. Cosentino, U. Pitea, D., Varì, MT, Moro, G., Saracino, GAA, Caria, P., Colombo, L., Forloni, G., Tagliavini F. and Salmona, M. The anti-fibrillogenic activity of tetracylines on PrP 106-126: a 3D-QSAR study. J Mol Model, 14: 987-94 (2008)
154. Natalello A, Prokorov VV, Tagliavini F, Morbin M, Forloni G, Beeg M, Manzoni C,
Colombo L, Gobbi M, Salmona M, Doglia SM. Conformational plasticity of the Gerstmann-Sträussler-Scheinker disease peptide as indicated by its multiple aggregation pathways. J Mol Biol. 381:1349-6 (2008)
155. Del Bo, R., Ghezzi, S., Scarlato, M., Albani, D. Galimberti, D., Lucca, U.,
Tettamanti, M., Scarpini, E., Forloni, G., Bresolin, N, Comi, GP. Role of VEGF gene variability in longevity: A lesson from the Italian population Neurobiol Aging. 29:1917-22 (2008)
156. Dossena, S., Imeri, L., Mangieri, M., Garofoli, A.,Ferrari, L, Senatore, A., Restelli,
E., Balducci, C., FiordalisoF., Salio, M., Bianchi, S., Fioriti, L., Morbin, M., Pincherle, A., Marcon, G., Villani, F., Carli, M., Tagliavini, F., Forloni G., Chiesa, R., Mutant Prion Protein Expression Causes Motor and Memory Deficits and Abnormal Sleep Patterns in a Transgenic Mouse Model Neuron 60: 598-609 (2008)
157. Albani D, Prato F, Fenoglio C, Batelli S, Dusi S, De Mauro S, Polito L, Lovati C,
Galimberti D, Mariani C, Scarpini E, Forloni G.Association study to evaluate the serotonin transporter and apolipoprotein E genes in frontotemporal lobar degeneration in Italy. J Hum Genet. 53:1029-33 (2008)
2009 158. Colombo, A., Bastone, A., Ploia, C., Sclip, A., Salmona, M. Forloni, G. Borsello,
TJNK regulates APP cleavage and degradation in a model of Alzheimer's disease Neurobiol Dis 33: 518-25. (2009)
159. Serretti A., Olgiati P., Politis A., Malitas P., Albani D., Dusi S., Polito L., De
Mauro S., Zisaki A., Piperi C., Liappas I., Stamouli E., Mailis A., Atti AR., Morri M., Ujkaj M., Batelli S., Forloni G., Soldatos C., Papadimitriou G., De Ronchi D., Kalofoutis A.Lack of association between interleukin-1 alpha rs1800587 polymorphism and Alzheimer‚s Disease in two independent European samples ‰ J Alzh Dis. 16: 181-7 (2009)
160. Forloni, G. Salmona, M, Marcon, G. Tagliavini, F. Tetracyclines and prion
infectivity. Infect Disord Drug Targets. 9: 23-30 (2009)
161. Serretti A, Liappas I, Mandelli L, Albani D, Forloni G, Malitas P, Piperi C, Politis A, Tzavellas EO, Papadopoulou-Daifoti Z, Zisaki A, Prato F, Batelli S, Polito L, De Ronchi D, Kalofoutis A. TPH2 gene variants and anxiety during alcohol detoxification outcome. Psychiatry Res 167: 167.14 (2009)
162. Gallucci M, Antuono P, Ongaro F, Forloni PL, Albani D, Amici GP, Regini
C.Physical activity, socialization and reading in the elderly over the age of seventy: What is the relation with cognitive decline? Evidence from "The Treviso Longeva (TRELONG) study Arch Gerontol Geriatr. 48: 284-6 (2009)
20
163. Albani D, Batelli S, Vittori, A., Pesaresi, M., Gajo, G., Angeli, S., Zanardo, A.,
Gallucci, M. Forloni, G. Insulin-like growth factor 1 receptor (IGF-1R) polymorphism rs2229765 affects male longevity in the Italian population: a genetic study and evaluation of plasma IGF-1 from the Treviso Longeva (TRELONG) study BMC Geriatr. 21;9:19 (2009)
164. Albani, D., Vittori, A. Batelli, S. Prato, F. Polito, L., De Mauro, S., Galimberti, D.,
Scarpini, E., Lovati, C., Marianio, C., Goldwurm, S., Forloni, G. Serotonin transporter gene polymorphic element 5-HTTLPR increases the risk of sporadic Parkinson's disease in Italy. Eur Neurology 62:120-123 (2009)
165. Albani D, Batelli S, Polito, L., Prato, F. Pesaresi, M., Gajo, G., Angeli, S.,
Zanardo, A., Gallucci, M. Forloni, G. Interleukin-6 (IL-6) plasma level increases with age in an Italian elderly population (“Treviso Longeva”study) with a sex-specific contribution of IL-6 rs1800795 polymorphism
Age (Dordr). 31: 155-62 (2009) 166. Albani, Prato, F., lovati, C., Tettamanti, M., Galimberti, D., Restelli, I.Mariani, C,
Quadri, P., Scarpini, E., Lucca, U., Forloni, G. The serotonin transporter promoter polymorphic region is not a risk factor for Alzheimer’s disease related behavioral disturbances. J. Alzh Dis 17: 1–6 (2009)
167. Albani, D. Polito, L., Batelli, S., De Mauro, S. Fracasso, C., Martelli, G.,
Colombo, L. Manzoni, C., Salmona, M., Caccia, S., Negro, A., Forloni, G. The SIRT1 activator resveratrol protects SKNBE cells from oxidative stress and against toxicity due to a synuclein or amyloid 42 peptide J.Neurochem 110: 1445-1456 (2009)
168. Albani, D., Prato, F., Tettamanti, M., Lovati, C., Galimberti, D., Mariani, C.,
Lucca, U., Quadri, PL., Scarpini, E., Forloni, G. The Serotonin Transporter Promoter Polymorphic Region is not a Risk Factor for Alzheimer Disease Related Psychological J Alzh Dis. 18:125-30 (2009)
169. Colombo, L., Piovesan, P. Ghirardi, O, Salmona, M. Forloni, G. ST1859 reduces
prion infectivity and increase survival in experimental scrapie Arch Virology 154: 1539-44, (2009)
170. Drago, A., Liappas, I., Petio, C., Albani., A., Forloni, G. Malitas, P., Piperi, C.,
Politis, A. , Tzavellas, EO., Zisaki, KK., Prato, F., Batelli, S., Polito, L. De Ronchi, G., Paparrigopoulos, T., Kalofoutis, A. Serretti A. Epistasis between IL1A, IL1B, TNF, HTR2A, 5-HTTLPR and TPH2 Variations Does Not Impact Alcohol Dependence Disorder Features Inter, J Envir. Res & Publ. Health 6:1980-90, (2009)
171. Fenoglio C, Galimberti D, Cortini F, Kauwe JS, Cruchaga C, Venturelli E, Villa
C, Serpente M, Scalabrini D, Mayo K, Piccio LM, Clerici F, Albani D, Mariani C, Forloni G, Bresolin N, Goate AM, Scarpini E. Rs5848 Variant Influences GRN mRNA Levels in Brain and Peripheral Mononuclear Cells in Patients with Alzheimer's Disease. J Alzheimers Dis. 8: 603-12 (2009)
21
172. Giordano C, Albani D, Gloria A, Tunesi M, Batelli S, Russo T, Forloni G,
Ambrosio L, Cigada A. Multidisciplinary perspectives for Alzheimer's and Parkinson's diseases: hydrogels for protein delivery and cell-based drug delivery as therapeutic strategies. Int J Artif Organs. 32: 836-50 (2009)
2010
173. Ploia, C., Sclip, A., Colombo, A., Repici, M., Gardoni, F., Di Luca, M., Forloni,
G., Antoniou X., and Borsello T. Role of Glycogen Synthase Kinase-3 in APP Hyperphosphorylation Induced by NMDA Stimulation in Cortical Neuron Pharmaceuticals 3: 42-58 (2010)
174. Albani, D. Polito, L. Forloni, G. Sirtuins as novel targets for Alzheimer's disease
and other neurodegenerative disorders: experimental and genetic evidence. J Alzheimers Dis. 19:11-26. (2010)
175. Balducci, C., Beeg, M., Stravalaci, M., Bastone, A.,, Sclip, A., Biasini, E.,
Tapelll., Colombo, L. Canzoni, C., Borsello, T., Chiesa, R., Gobbi, M., Salmona M. Forloni, G., A� oligomers impair memory independently of cellular prion poteinProc. Natl. Acad. Sci USA, 107: 2295-2300 (2010)
176. Politis, A., Olgiati, P., Malitas, P.,Albani, D., Signorini, A., Polito, A., De Mauro, S., Zisaki, A., Piperi, C., Stamouli, E., Mailis, A., Batelli, S., Forloni, G., De Ronchi, D., Kalofoutis, A., Liappas, I, Sorretti, A., Vitamin B12 levels in Alzhiemr’s disease association with clinical features and cytokine production J. Alzh Dis 19:481-8 (2010)
177. Olgiati P, Politis A, Malitas P, Albani D, Dusi S, Polito L, De Mauro S, Zisaki A,
Piperi C, Stamouli E, Mailis A, Batelli S, Forloni G, De Ronchi D, Kalofoutis A, Liappas I, Serretti A. APOE epsilon-4 allele and cytokine production in Alzheimer's disease. Int J Geriatr Psychiatry. 25: 338-44 (2010)
178. Bruni, AC., Bernardi, L. Colao, R., Rubino, E., Smirne, N., Frangipane, F., Terni,
B., Curcio1, SAM. Mirabelli, M.,Maletta, R., Anfossi, M.,Gallo, M., Geracitano, S., Tomaino, c., Muraca, MG., Leotta A., Lio, G., Ponessi, L., Rainero, I., Sorbi, S., Nee. L., Milan, G., Pappatà, S.,Postiglione, A., Abbamondi, N., Forloni, G., St. George Hyslop., p., Rogaeva, E., Bugiani, O., Giaccone, G., Foncin, JF., Spillantini, MG., Puccio, G. Worldwide distribution of PSEN1 Met146Leu mutation: A large variability for a founder mutation, Neurology 74: 798-806 (2010)
179. Lovati, Galimberti, D., Bertora, P., Venturelli, E., Cislaghi, G., Guidi, I., Fenoglio,
C., Cortini, F., Clerici, F., Finazzi, D., Albani, D., Forloni, G. Scarpini, E., Mariani, C. ApoE �2 decreases the susceptibility to develop Alzheimer’s disease but not other types of dementia Inter. J. Mol Epidem Genet 1:193-200 (2010)
180. Polito L., Kehoe, P. Forloni, G. Albani, D. The molecular genetics of sirtuins:
association with humanlongevity and age-related diseases. Int J Mol Epidemiol Genet 2010;1:214-225. (2010)
22
181. Lescai, F., Pirazzini, C. D’Agostino. G. Santoro, A., Ghidoni, R., Benussi, L. Galimberti, D., Esposito, F., Marchegiani, F., Cardelli, M., Olivieri, F., Nacmias, B., Sorbi, S., Bagnoli, S., Tagliavini F., Albani, D., Martinelli Boneschi, F., Binettii, G., Forloni, G., Quadri, PL., Scarpini, E. and Franceschi, C. Failure to replicate an association of the rs5984894 SNP in a collection of 1.222 Alzheimer’s disease affected patient J Alzheimer Disease. 21: 385-8 (2010)
182. Balducci, C., Tonini, R., Zianni, E., Nazzaro, C., Salio, M., Vismara, L.,
Fiordaliso, F., Gardoni, F., Di Luca, M., Carli, M., Forloni G. Cognitive deficits associated with loss of synaptic metaplasticity precede plaque deposition in APP23 transgenic mice. J Alzheimer Disease 21:1367-1381 (2010)
183. Gallucci, M., Ongaro, F., Meggiolaro, P., Antuono, P., Gustafson, DR., Forloni,
GL., Albani, D., Gajo, GB, Durante, E., Caberlotto, L. Zanardo, A., Siculi, M., Muffato, Regini, C. Factors related to disability: Evidence from the “Treviso Longeva (TRELONG) Study”. Arch Gerontol Geriatr. Jun 8. [Epub ahead of print] (2010)
184. Albani D, Polito L, Signorini A, Forloni G. Neuroprotective properties of resveratrol
in different neurodegenerative disorders. Biofactors. 36:370-6 (2010)
185. Urru, S., Veglianese, P., De Luigi, A., Fumagalli, E:, ; Erba, E., Gonella Dazia, R., ; Carrà, A., Davoli, E., Borsello, T., Forloni, G., Monzani, E., Pengo, N., Cascio, P., Cenci, S., Sitia, R., Salmona, M., A New Fluorogenic Peptide Determines Proteasome Activity in Single Cells. J Med Chem. 53:7452-60 (2010)
186. Restelli E, Fioriti L, Mantovani S, Airaghi S, Forloni G, et al. (2010) Cell Type-
Specific Neuroprotective Activity of Untranslocated Prion Protein. PLoS ONE 5: e13725.doi:10.1371/journal.pone.0013725 (2010)
187. Epis, R., Marcello, E., Gardoni, F., Csba, V., Malinverono, M., Balducci, C.,
Colombo, A., Borroni, B., Hugo, V., Giustetto, M, Borsello, T., Forloni, G., Cattabeni, F., Padovani, A., Di Luca, M. Blocking ADAM10 synaptic trafficking generates a model of sporadic Alzheimer's disease. Brain. 133: 3323-35 (2010)
2011 188. Forloni, G. & Balducci, C. Prion protein and amyloid oligomers: Fatal
attraction? Prion 5: 10-15 (2011) 189. Airoldi, C.,Colombo,L., Manzoni,C., Sironi, E., Natalello, A., Doglia, SM.,
Forloni,G., Tagliavini, F., Del Favero,E., Cantù,L., Nicotra, F., Salmona, M., Tetracycline prevents A oligomer toxicity through an atypical supramolecular interaction Org Biomol Chem. 9: 463-72 (2011
190. Finch, N Carrasquillo, MM., Baker, M., Rutherford, NJ Coppola, G. DeJesus-
Hernandez, M., Crook, R., Hunter, T., Ghidoni, R., Benussi, L., Crook, J., Finger, E., Hantanpaa, K., Karydas, AM., Sengdy, P., Gonzalez J., Seeley, WW., Johnson, N., Beach, TG.,Mesulam, M., Forloni, G., Kertesz, P.,
23
Knopman, DS., Uitti, R., White III, CL., Caselli, R., Lippa, C., Bigio, EK., Wszolek, ZK., Binetti, G., Mackenzie, IR., Miller, BL., Boeve, BF., Younkin, SG., Dickson, DW., Petersen, R.C. Graff-Radford, NR., Geschwind, DH, and Rademakers, R. TMEM106B regulates progranulin levels and modulates disease penetrance in GRN mutation carriers Neurology 76: 467-74 (2011)
191. Crestini, A., Piscopo, P., Iazeolla, MV, Albani, D., Rivabene R., Forloni, G.,
Confaloni, A. Rosuvastatin and Thapsigargin modulate �secretase genes expression and APP processing in a human neuroglioma model.
J Mol Neurosci. 43:461-469 (2011) 192. Lescai, F., Chiamenti, AM., Codemo, A., Pirazzini,C., D'Agostino, G., Ruaro,
C., Ghidoni, R., Benussi, L., Galimberti, D., Esposito, F., Marchegiani, F:, Cardelli, M., Olivieri, F., Nacmias, B., Sorbi, S., Tagliavini, F., Albani, D.,Martinelli Boneschi, F., Binetti, G., Santoro, A., Forloni G., Scarpini, E., Crepaldi, G.,Gabelli, G., and Franceschi, C. An APOE haplotype decreasing e4 expression doubles Alzheimer’s Disease risk J Alzheimers Dis. 24:235-45 (2011)
193. Gallucci M, Ongaro F, Meggiolaro S, Antuono P, Gustafson DR, Forloni GL,
Albani D, Gajo GB, Durante E, Caberlotto L, Zanardo A, Siculi M, Muffato G, Regini C. Factors related to disability: Evidence from the "Treviso Longeva (TRELONG) Study". Arch Gerontol Geriatr. 52:309-16 (2011)
194. Perale, G., Veglianese, P., Rossi, F., Peviani, M., Santoro, M., Llupi, D.,
Micotti, E., Forloni, G., Masi, M. In situ agar-carbomer hydrogel polycondensation: A chemical approach to regenerative medicine Materials letters 5: 1688-1692 (2011)
195. LI, M., Armelloni, S., Ikehata M., Corbelli, A., Pesaresi, M., Calvaresi, N.,
Giardino L., Mattinzoli, D., Nisticò, F., Andreoni, S., Puliti, A., Ravazzolo, R., Forloni, G., Messa, P., Rastaldi MP. Nephrin expression in adult rodent cns and interaction with glutamate receptors. J. Pathology ,225:118-128 (2011)
196. Gemma, S., Colombo, L., Forloni, G. Savini, L. Caccia, S., Salmona, M.,
Brindisi, Joshi, BP., Tripaldi, P, Giorgi, G., Taglialatela-Scafati, O., Novellino, E., Fiorini, I., Campiani, G., Butini, S., Diagnosing Alzheimer’s Disease: Pyrroloquinoxaline Hydrazones as Promising Molecular Scaffolds for Amyloid Imaging. J. Med Chem. 9: 5137-5148 (2011)
197. Quaglio E., Restelli, E. Garofoli, A., Dossena S., De Luigi, A., Tagliavacca, L.,
Imperiale, D., Migheli, A., Salmona, M., Sitia, R., Forloni, G. Chiesa R. Expression of Mutant or Cytosolic PrP in Transgenic Mice and Cells is not Associated with Endoplasmic Reticulum Stress or Proteasome Dysfunction. Plos One, 6(4):e19339 (2011)
198. Balducci, C. & Forloni G: APP transgenic mice: their use and limitations
Neuromolecular Med. 13:117-37 (2011) 199. Balducci, C., Mehdawy, B., Mare L. Giuliani, A., Lorenzini, L., Sivilia S.
Lanzillotta M., Samico, I., Pizzi, M., Usiello, A., Viscomi, RA., Ottonello,
24
S.,Villetti, G., Imbimbo BP., Nisticò G. Forloni, G., Nisticò, R. The -secretase modulator CHF5074 restores memory and hippocampal synaptic plasticity in plaque-free Tg2576 mice. J Alz Dis 24:799-816 (2011)
200. Ploia C, Sclip A, Antoniou X, Cardinetti D, Colombo Alessio, Canu N, Benussi
L, Ghidoni R, Forloni G, Borsello T Cell permeable JNK inhibitor peptide prevents tau hyperphosphorylation in Alzheimer's disease models J. Alz. Dis 26:315-329 (2011)
201. Polito L, Prato F, Rodilossi S, Ateri E, Galimberti D, Scarpini E, Clerici F,
Mariani C, Forloni G, Albani D.A novel study and meta-analysis of the genetic variation of the serotonin transporter promoter in the italian population do not support a large effect on Alzheimer's disease risk. Int J Alzheimers Dis.; 2011 : 312341 (2011)
202. Re F, Cambianica I, Zona C, Sesana S, Gregori M, Rigolio R, La Ferla B,
Nicotra F, Forloni G, Cagnotto A, Salmona M, Masserini M, Sancini G.Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model. Nanomedicine. 7: 551-559 (2011)
203. Batelli S, Peverelli E, Rodilossi S, Forloni G, Albani D. Macroautophagy and
the proteasome are differently involved in the degradation of alpha-synuclein wild type and mutated A30P in an in vitro inducible model (PC12/TetOn). Neuroscience. 10: 195:128-137 (2011)
204. Drago,V., Babiloni, C., Bartres-Faz, Caroli, A., Bosch, B., Hensch, T., Didic,
M., Kafki, H-W., Pievani. M., Jovicich, J., Venturi, L., Spitzer, P., Vecchio, F., Schoenknecht, P., Wiltfang, J., Redolfi, A., Forloni, G., Blin, O., Irving, E., Davis, C., Hardemark, H-G, Frisoni, G. Disease Tracking Markers for Alzheimer's Disease at the Prodromal (MCI) Stage. J. Alz. Dis. 26 (suppl.3) 159-199 (2011)
205. Albani, D., Mazzuco, S., Polito, L., Batelli, S., Ongaro, F., Gustafson, DR.,
Antuono, P., Gajo, G., Drante, E., Caberlotto, Zanardo, A.,Sicuri, M., Gallucci, M, Forloni, G., The insulin-like growth factor 1 receptor polymorphism rs2229765 and circulating interleukin-6 level affect male longevity in a population-based prospective study (Treviso Longeva- TRELONG). Aging Male 14: 257-264 (2011)
206. Giordano C, Albani D.; Gloria A.; Tunesi M.1; Rodilossi S; Russo T., Forloni G.,
Ambrosio L.,Cigada A., Nanocomposites for neurodegenerative diseases: hydrogelnanoparticle combinations for a challenging drug delivery. Int. J. Artif. Organ 34:1115-27 (2011)
207. Sclip A, Antoniou X, Colombo A, Camici GG, Pozzi L, Cardinetti D, Feligioni M,
Veglianese P, Bahlmann FH, Cervo L, Balducci C,Costa, C., Tozzi, A., Calabresi, P., Forloni, G., Borsello, T., c-Jun N-terminal kinase regulates Ab-oligomers and memory in Alzheimer’s mice. J Biol Chem. 28643871-80 (2011)
208. Polito L, Prato F, Rodilossi S, Ateri E, Galimberti D, Scarpini E, Clerici F,
25
Mariani C, Forloni G, Albani D. A novel study and meta-analysis of the genetic variation of the serotonin transporter promoter in the italian population do not support a large effect on Alzheimer's disease risk.Int J Alzheimers Dis. 2011:312341 (2011)
209. Perale G, Rossi F, Sundstrom E, Bacchiega S, Masi M, Forloni G, Veglianese
P. Hydrogels in spinal cord injury repair strategies. ACS Chem Neurosci. 2:336-45 (2011)
2012 210. Albani, D., Tettamanti, M., Batelli, S., Polito, L. Dusi, S., Ateri, E., Forloni, G.,
Lucca, U., Interleukin-1, Interleukin-1 and Tumor Necrosis Factor- genetic variants and risk of dementia n the very old: evidence from the "Monzino 80-plus" prospective study, Age (Dordr) 34:519-26 (2012)
211. Bigini, P., Diana, V., Barbera, S., Fumagalli, E., Micotti, E., Sitia, L., Paladini,
A., Bisighini, C., De Grada, L., Coloca, L., Colombo, L. Manca, P., Bossolasco, P., Malvestiti, F., Fiordaliso, F., Forloni, G., Morbidelli, M., Salmona, M., Giardino, D., Mennini, T., Moscatelli, D., Silani, V. and Cova L. Longitudinal tracking of human fetal cells labeled with super paramagnetic iron oxide nanoparticles in the brain of mice with motor neuron disease. PlosOne 7(2):e32326 (2012)
212. Biasini, E., Turnbaugh, J., Massignan, T., Veglianese, P., Forloni, G., Bonetto,
V., Chiesa, R., Harris, D.The toxicity of a mutant prion protein is cell-autonomous, and can be suppressed by wild-type prion protein on adjacent cells PlosOne 2012;7(3):e33472 (2012)
213. Rossi, F.; Veglianese, P.; Santoro, M.; Papa, S.; Rogora, C.; Dell’Oro, V.;
Forloni, G.; Masi, M.; Perale, G.Sustained Delivery of Chondroitinase ABC from Hydrogel System. J. Funct. Biomater. 3: 199-208 (2012)
214. Olgiati, P. Politis, A, Albani, D, Rodilossi, S. Polito, L, Ateri , E., L. Zisaki, A.,
Piperi, C. Liappas L., Stamouli E., Mailis , A., Atti AR, Ferrari , A., Morini V, Moretti, F., Biella G, Forloni , G., Papadimitriou NG, De Ronchi, D., Kalofoutis, A., Sorretti, A.. Association of SORL1 alleles with late-onset Alzheimer's Disease. Findings from the GIGAS_LOAD study and mega-analysis. Current Alzheimer Res. 9:491-409 (2012)
215. Gallucci, M., E. Mariottia, E., Saraggi, D; Stecca, T., Oddo,MG. Bergamelli,C,
Boldrini P.. Mazzuco S., Ongaro, F., Mecocci, P. Di Paola, F., Bendini, M, Forloni, G., Albani, D., Antuono P., Caberlotto, L. Zanardo A., Siculih, M., Gajoi, GB., Durante G., Buscato G., The Treviso Dementia (Tredem) Study: A Biomedical, neuroradiological, neuropshycological and social investigation on dementia in the north-east of italy. Fraility and Aging 1: 24:31 (2012)
216. Senatore, A., Colleoni, S., Verderio, C., Restelli, E., Morini, R., Codliffe, SB,
Bertani, I., Mantovani, S., Canovi, M. Micotti, E., Forloni, G., Dolphin AC.,
26
Matteoli, M., Gobbi, M., Chiesa R. Mutant Prion Protein Suppresses Glutamatergic Neurotransmission in Cerebellar Granule Neurons by Impairing Membrane Delivery of Voltage-gated Calcium Channel 2 -1 Subunit.
Neuron 74: 300-313 (2012) 217. Perale, G. Rossi, F., Santoro, M., Peviani, M., Llupi, D., Torriani, Micotti, E.,
Previdi, Cervo, L., Sundstrom, E., Bocaccini, AR., Masi, M., Forloni, G., Veglianese, P. Multiple drug delivery hydrogel system for spinal cord injury repair strategies J Control Release. 159: 271-80 (2012)
218. Albani D.,Martinelli Boneschi, F., Biella, G., Giacalone, G.,Lupoli, S., Clerici,
F.,Benussi, L., Ghidoni, R., Galimbert, D., Squitti, R., Mariani, S., Confaloni, A., Bruno, G., Mariani, C., Scarpini, E., Binetti, G., Magnani, G., Franceschi, M., Forloni, G. Replication Study To Confirm the Role of CYP2D Polymorphism rs1080985 on Donepezil Efficacy in Alzheimer’s Disease Patients. J Alzheimers Dis. 30:745-9 (2012)
219. Puoti, G., Bizzi, A., Forloni G., Safar JG.,Tagliavini, F., Gambetti, P. Sporadic
human prion diseases: molecular insights and diagnosis. Lancet Neurology 11: 618-28 (2012)
220. Gustafson, DR:, Mazzuco, S., Ongaro, F:, Antuono, DP, Forloni, G., Albani,, D.,
Gajo,GB., Durante, E:, Caberlotto, L., Zanardo, A:, Siculi, M., Gallucci, M. BMI, MMSE, APOE and mortality: the “treviso longeva” (TRELONG) study J. Am.Ger Soc. 20: 594-602 (2012).
221. De Paola M, Mariani A, Bigini P, Peviani M, Ferrara G, Molteni M, Gemma S,
Veglianese P, Castellaneta V, Boldrin V, Rossetti C, Chiabrando C, Forloni G, Mennini T, Fanelli R. Neuroprotective effects of Toll-like receptor 4 antagonism in spinal cord cultures and in a mouse model of motor neuron degeneration. Mol Med. 18: 971-81 (2012)
222. Forloni G. Responsible Research in Nanotechnology. J. Nanoparticles Res. DOI 10.1007/s11051-012-1007-1 (2012) 223. Olgiati P, Politis A, Albani D, Rodilossi S, Polito L, Ateri E, Zisaki A, Piperi C,
Liappas I, Stamouli E, Mailis A, Atti AR, Ferrari B, Morini V, Moretti F, Biella G, Forloni G, Papadimitriou GN, Ronchi DD, Kalofoutis A, Serretti A. Association of SORL1 alleles with late-onset Alzheimer's disease. findings from the GIGAS_LOAD study and mega-analysisCurrent Alzheimer Res. 9: 491-9 (2012)
2013 224. Forloni, G., Sclip, A., Borsello, T., Balducci, C. The neurodegeneration in
Alzheimer's disease and the prion protein. Prion 7: 60-65 (2013) 225. Babiloni, C., Infarinato; F. Aujard; a., Bastlund; J.F, Bentivoglio, M., Bertini, G. Del
Percio;C Fabene, P., Forloni, GL., Herrero; MT., Noè, FM., Pifferi, F., Ros-Bernal, F Christensen; Dix, S., Richardson; J. Lamberty; J. Rossini; PM, Drinkenburg W. Effects of pharmacological agents and other challenges on
27
electroencephalographic rhythms in preclinical studies: towards translational models for drug discovery in alzheimer's disease Clinical Neurophysiology 124:437-5 (2013)
226. Rossi, F., Perale, G., Papa, S., Forloni, G., Veglianese, P., Current options to
drug delivery to the spinal cord. Current Expert Opinion 10: 385-96 (2013) 227. Olgiati P, Politis A, Albani D, Rodilossi S, Polito L, Zisaki A, Piperi C, Liappas I,
Stamouli E, Mailis A, Batelli S, Forloni G, Marsano A, Balestri M, Soldatos CR, De Ronchi D, Kalofoutis A, Serretti A. Effects of SORL1 Gene on Alzheimer's Disease. Focus on Gender, Neuropsychiatric Symptoms and Pro-Inflammatory Cytokines. Curr Alzheimer Res. 10:154-64 (2013)
228. Biella, G., Franceschi, M., De Rino, Davin A., Martinelli Boneschi, F.,
Giacalone, G., Lupoli, S., Bountris, P., Haritou, M., Magnani, G., Forloni, G., Albani, D., Multiplex assesment of a panel of 16 serum molecules for the differential diagnosis of Alzheimer's disease. Amer. J. Neurod. Dis 2:40-45 (2013)
229 Fluharty, BR, Biasini E.,Stravalaci, M., Sclip, A., Diomede, L., Balducci, C., La
Vitola, P., Messa, M., Colombo, L. Forloni, G., Borsello, T., Gobbi, M., Harris, D. An n-terminal fragment of the prion protein binds to amyloid-β oligomers and inhibits their neurotoxicity in vivo. J Biol Chem 288: 7857-66 (2013)
230. Galluccl, M. , Mazzucco, S., Ongaro, F., Di Giorgi, E., Mecocci, P., Cesari, M.,
Albani, D., Forloni, G., Durante, E., Gajo, G., Zanardo, A., Siculi, M., Caberlotto, L., Regini, C., Body mass index, physical performance, lifestyles and cognitive decline: the TREVISO LONGEVA (TRELONG) Study. J Nutr, Health & Aging. 17: 378-84 (2013
231. Rossi F., Ferrari, R., Papa, S., Moscatelli, D., Casalini T., Forloni, G., Perale G.,
Veglianese P. Tunable Hydrogel - Nanoparticles Release System for Sustained Combination Therapies in the Spinal Cord. Colloids Surf B
Biointerfaces.108C:169-177 (2013) 232 Martinelli Boneschi, F., Giacalone,G., Magnani, G., Biella, G., Coppi, E.,
Santangelo, R., Brambilla, P., Esposito, F., Lupoli, S., Clerici, F., Benussi, L., Ghidoni, R., Galimberti, D., Squitti, R., Confaloni, A., Bruno, G., Pichler, S., Mayhaus, M., Riemenschneider, M., Mariani, C., Comi, G., Scarpini, E., Binetti, G., Forloni, G. Franceschi, M., Albani D. Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to acetylcholinesterase inhibitors. Neurobiol Aging. 34:1711.e7-13 (2013)
233. Polito, l, Kehoe P, Davin, A., Ghidoni, R., Benussi, L., Quadri, PL, Lucca, U.,
Tettamanti, M., Mariani, C., Forloni, G., Albani, D. The SIRT2 polymorphism rs10410544 as susceptibility factor for Alzheimer’s disease. Alzheimer & Dementia 9: 392-399 (2013)
234 Snellman A, López-Picón FR, Rokka J, Salmona M, Forloni G, Scheinin M,
Solin O, Rinne JO, Haaparanta-Solin M.Longitudinal Amyloid Imaging in Mouse
28
Brain with 11C-PIB: Comparison of APP23, Tg2576, and APPswe-PS1dE9 Mouse Models of Alzheimer Disease. J Nucl Med. 54:1434-1441 (2013)
235. Stoilova, T, Colombo, L., Forloni, G., Tagliavini, F., Salmona, M., A new face
for old antibiotics: tetracyclines in treatment of amyloidoses J Med Chem. 56: 5987-6006 (2013) 236 Mandelli L., Marangoni, C., Liappas I. Albani, D., Forloni, G. Piperi C., Zisaki
A., Tzavellas, EO., Prato, F., Batelli S., Pesaresi M., Fabbri, C., Kalofoutis, A., De Ronchi, A., Serretti, A., Impact of 5HTTLPR polymorphism over psychopathologic dimensions in alcoholics patients after detoxification treatment. J Add Medicine 7:72-3 (2013)
237. Forloni G, Artuso V, Roiter I, Morbin M, Tagliavini F. Therapy in Prion
Diseases.Curr Top Med Chem. 13: 2465-2476 (2013 ) 238. Porcelli, S., Salfi, R., Politi, A., Atti, AR., Albani, A., Chierchia, A., Polito, L.,
Zisaki, A., Piperi, C., Liappas, I., Stamouli , E., Mailis, A., Biella, G., Forloni, G., Bernabei, V., Ferrari, B., Lia, L., Papadimitrio, GN., De Ronchi, D., Serretti, A. Association between Sirtuin 2 gene rs10410544 polymorphism and depression in Alzheimer's disease in two independent European samples. J Neural Transm. 120: 1709-15.(2013)
239. Papa S, Rossi F, Ferrari R, Mariani A, De Paola, M, Caron I, Fiordaliso F,
Bisighini C, Sammali E, Colombo C, Gobbi M, Canovi M, Lucchetti J, Peviani M, Forloni G, Perale G, Moscatelli D, Veglianese P. Selective treatment of activated pro-inflammatory macrophage/microglia in spinal cord injury ACSNano 7: 9881-95 (2013)
240. Guaita, A., Colombo, M., Vaccaro, R., Fossi, S.,Vitali, SF., Forloni, G., Polito, L.,
Davin, A., Ferretti, VV., Villani, S. Brain aging and dementia during the transition from late adulthood to old age: design and methodology of the “Invece.Ab” population-based study. BMC Geriatr. 24;13:98 (2013)
241: Tunesi, M., Batelli, S. Rodilossi, S., Russo T., Grimaldi A., Forloni, G.,
Ambrosio, L., Cigada, A., Gloria, A., Albani, D., Giordano, C. Injectable semi-interpenetrating polymer networks in neurodegenerative disorders: characterization and in vitro/in vivo biocompatibility. Int J Artif Organs 36: 762-74 (2013)
242. Albani, D., Gloria, A., Giordano, C., Rodilossi, S., Russo T., D'amora, U.,
Tunesi, M., Cigada, A., Ambrosio, L., Forloni, G., Hydrogel-based nanocomposites and mesenchymal stem cells: a promising synergiostic strategy for neurodegenerative disorders therapy. The Scientific World Journal http:// dx.doi.org/10.1155/2013/270260 (2013)
243 . Marizzoni M., Forloni G., Frisoni, G. New paradigm for testing AD drugs –
Neuroimaging biomarkers as surrogate outcomes homologous in animals and human Drug Discovery Today: Therapeutic Strategies. 10 (2) e63–e71 (2013
29
2014 244. Benussi, L. Rossi, G., , Gliomma M., Tonoli, E., Piccoli, E., Fostinelli, S.,
Paterlini, A., Flocco, R., Albani, D., Pantieri, R., Cereda, C:, Forloni, G., Tagliavini, F., Ghidoni, R. C9ORF72 hexanucleotide repeats number in FTLD: genotype-phenotype correlation study. J Alzheimers Dis. 38:799-808 (2014)
245. Albani, D., Ateri E., Mazzucco, S., Ghilardi, A., Rodilossi, S., Biella G.,
Ongaro, F., Antuono, P., Boldrii, P., Di Giorgi, E., Frigato, A., Durante, E., Caberlotto, L., Zanardo, A., Siculi, M., Gallucci, M. and Forloni, G. Modulation of human longevity by SIRT3 single nucleotide polymorphisms in the population-based prospective study “Treviso Longeva (TRELONG)”.
Age 36:469-478 (2014) 246. Papa S, Ferrari R, Mariani A, De Paola, M, Rossi F, Mariani A, Caron I, ,
Sammali E, Peviani M, Dall'Orso V, Colombo C, Morbidelli M,, Forloni G, Perale G, Moscatelli D, Veglianese P. Polymeric Nanoparticle System to Target activated microglia/macrophages in Spinal Cord Injury.
J Controll Release 28:15-26 (2014) 247. Haïk, S, Marcon, Coudert M, Tettamanti M, Welaratne A, Giaccone G,
Azimi S, Pietrini V, Fabreguettes, J-R, Imperiale, D, Cesaro, P, Buffa, C, Aucan, C, Lucca, U, Mallet, A, Suardi, S, Tranchant, C, Zerr, I, Houillier, C, Redaelli, V, Vespignani, H, Campanella A, Sellal, F; Gobbi, M, Seilhean, D, Canovii, M, Sedel, F, Di Fede, G, Laplanche, JL, Pocchiari, M, Salmona, M, Forloni, G, Brandel, J-P Tagliavini, F. Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomized, double-blind, placebo-controlled trial Lancet Neurol. 13:150-8 (2014)
248 Grigoryan G, Biella G, Albani D, Forloni G, Segal M Stress Impairs Synaptic
Plasticity in Triple-Transgenic Alzheimer's Disease Mice: Rescue by Ryanodine. Neurodegener Dis. 13:135-82013 (2014) 249. Bonavita V, Padovani A, Bruni A, Pantoni L, Caltagirone C, Parnetti L, Clerici
F, Perani D, Di Luca M, Sorbi S, Forloni G, Tagliavini F, Frisoni G, Tempini MG, Mariani C, Venneri A, Musicco M. IX Congresso Sindem: Italian Association for the study of Dementia linked to the Italian Neurological Society (SIN). J Alzheimers Dis. 2014;41(0):S1-S68. doi: 10.3233/JAD-149999.
251. Balducci, C. Forloni, G. In vivo application of beta amyloid oligomers: a simple
tool to evaluate mechanisms of action and new therapeutic approaches. Current Pharmaceutical Design 20: 2491-2505 (2014)
252. Rokka J, Snellman A, Zona C, La Ferla B, Nicotra F, Salmona M, Forloni G,
Haaparanta-Solin M, Rinne JO, Solin O.Synthesis and evaluation of a 18F-curcumin derivate for –amyloid plaque imaging Bioorganic Medical Chemistry 22: 2753-62 (2014)
30
253. Ferrari R, Hernandez DG, Nalls MA, Rohrer JD, Ramasamy A, Kwok JB, Dobson-Stone C, Brooks WS, Schofield PR, Halliday GM, Hodges JR, Piguet O, Bartley L, Thompson E, Haan E, Hernández I, Ruiz A, Boada M, Borroni B, Padovani A, Cruchaga C, Cairns NJ, Benussi L, Binetti G, Ghidoni R, Forloni G, Galimberti D, Fenoglio C, Serpente M, Scarpini E, Clarimón J, Lleó A, Blesa R, Waldö ML, Nilsson K, Nilsson C, Mackenzie IR, Hsiung GY, Mann DM, Grafman J, Morris CM, Attems J, Griffiths TD, McKeith IG, Thomas AJ, Pietrini P, Huey ED, Wassermann EM, Baborie A, Jaros E, Tierney MC, Pastor P, Razquin C, Ortega-Cubero S, Alonso E, Perneczky R, Diehl-Schmid J, Alexopoulos P, Kurz A, Rainero I, Rubino E, Pinessi L, Rogaeva E, St George-Hyslop P, Rossi G, Tagliavini F, Giaccone G, Rowe JB, Schlachetzki JC, Uphill J, Collinge J, Mead S, Danek A, Van Deerlin VM, Grossman M, Trojanowski JQ, van der Zee J, Deschamps W, Van Langenhove T, Cruts M, Van Broeckhoven C, Cappa SF, Le Ber I, Hannequin D, Golfier V, Vercelletto M, Brice A, Nacmias B, Sorbi S, Bagnoli S, Piaceri I, Nielsen JE, Hjermind LE, Riemenschneider M, Mayhaus M, Ibach B, Gasparoni G, Pichler S, Gu W, Rossor MN, Fox NC, Warren JD, Spillantini MG, Morris HR, Rizzu P, Heutink P, Snowden JS, Rollinson S, Richardson A, Gerhard A, Bruni AC, Maletta R, Frangipane F, Cupidi C, Bernardi L, Anfossi M, Gallo M, Conidi ME, Smirne N, Rademakers R, Baker M, Dickson DW, Graff-Radford NR, Petersen RC, Knopman D, Josephs KA, Boeve BF, Parisi JE, Seeley WW, Miller BL, Karydas AM, Rosen H, van Swieten JC, Dopper EG, Seelaar H, Pijnenburg YA, Scheltens P, Logroscino G, Capozzo R, Novelli V, Puca AA, Franceschi M, Postiglione A, Milan G, Sorrentino P, Kristiansen M, Chiang HH, Graff C, Pasquier F, Rollin A, Deramecourt V, Lebert F, Kapogiannis D, Ferrucci L, Pickering-Brown S, Singleton AB, Hardy J, Momeni P.. Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurol 13:686-99 (2014)
254. Albani D & Forloni G.The catalytic activity of sirtuins in physiology and disease
from the epigenetic point of view Epigenetic of Neurodegenerative Diseases 1:32-39 (2014)
255. Snellman A, Rokka J, Lopez-Picon FR, Eskola O, Salmona M, Forloni G,
Scheinin M, Solin O, Rinne JO, Haaparanta-Solin M. In vivo PET imaging of beta-amyloid deposition in mouse models of Alzheimer's disease with a high specific activity PET imaging agent [18F]flutemetamol. EJNMMI Research 4:37 (2014)
256 Caron I, Papa S, Rossi F, Forloni G, Veglianese P Nano-vector mediated
drug delivery for spinal cord injury. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 6:506-15 (2014)
257. Polito L, , Chierca A, Tunesi M, Kehoe PG Albani D, Forloni G Environmental
enrichment lessens cognitive decline in APP23 mice without affecting brain sirtuin expression J Alzheimers Dis.42:851-64 (2014)
258. Gallucci, M. Flores-Obando, R., Mazzuco, S., Ongaroc, F., Digiorgi, E.,
Boldrini, P., Durante, E., Frigato, A., Albanei, D., Forloni, G., Zanardo, A., Siculi, M, Caberlotto, A.,Taiolil, E. Melatonin and the Charlson Co-morbidity
31
Index (CCI): the Treviso Longeva (Trelong) Study Int J Biol Mark 29: e253-60 (2014)
259. Balducci C., Minniti, S., Lavitola, P., Zotti, M., Sancini, G, Cagnotto, A,
Salmona M, Haaparanta-Solin M, Forloni G, Masserini M, Re F. Efficacy of a nanomedicine-based therapeutics in Alzheimer's mouse model
J Neurosci 34:14022-14031 (2014) IN PRESS
260. Fabbri C, Souery D, Calati R, Crisafulli C, Chierchia A, Albani D, Forloni G, Chiesa A, Martines R, Sentissi O, Mendlewicz J, De Girolamo G, Serretti A. Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients. J Neural Transm. 2014 Aug 17. [Epub ahead of print]
261. Micotti E, Paladini A, Balducci C, Tolomeo D, Frasca A, Marizzoni M, Filibian
M, Caroli A, Valbusa G, Dix S, O'Neill, M, Ozmen L, Czech C, Richardson CJ, Frisoni GB, Forloni G Striatum and entorhinal cortex common neuropathological targets in mouse models of Alzheimer's disease
Neurobiology of Aging
Forloni CV 22/10/2014
32
Review articles and book chapters 1. Ladinsky H., Consolo S., Tirelli A.S., Forloni G., Segal M. Regulation of cholinergic
activity in the rat hippocampus: In vivo: effects of oxotremorine and fenfluramine. IN: "Cholinergic mechanisms" Pepeu, G. & Ladinsky H. (Eds) Plenum Press, New
York pp. 781-793 (1981). 2. Ladinsky H., Sieklucka M., Fiorentini F., Forloni G., Cicioni P., Consolo S. Regulation of drugs affecting striatal cholinergic activity by corticostriatal
projections. IN: "Dynamics of cholinergic function" Hanin I.(ed) Plenum Press, New York, pp. 973-979 (1986).
3. Ladinsky H., Consolo S., Forloni G., Fiorentini F., Fisone G. Influence of frontal decortication on drugs affecting striatal cholinergic activity
and cataleptic behavior: Restoration studies. IN: "Neurobiology of acetylcholine" Dun N.J. & Perlam, R.L. (Eds) Plenum Press,
New York, pp. 403-416 (1987). 4. Coyle, J.T. Robinson, M.B. Blakely R. and Forloni G. The neurobiology of N-acetyl-
aspartyl-glutamate IN: "Allosteric Modulation of Amino Acid Receptors: Therapeutic Implications"
A.Barnard & E. Costa (Eds) Raven Press NY , pp.319-333 (1989) 5. Frattura L. Forloni G. Lucca U. Menasce G. Tettamanti M, Tiraboschi P. and Spagnoli
A.Temi di Psicogeriatria Ricerca & Pratica 26: 35-104 (1989) 6. Forloni G. -amyloid neurotoxicity Functional Neurology, 8: 211- 225 (1993) 7. Forloni, G. Espressione e neurotossicità della proteina ß amiloide in colture neuronali
primarie. in:“Colture neuronali, un modello per lo studio dell’invecchiamento cerebrale”, Annunziato L. e Spano P.F. (eds ) Pythagora Press , Roma (1993) pp. 55- 66
8. Spagnoli, A. Forloni, G. Furlanetto, M; Lucca, U., Tettamanti, M. and Tiraboschi,P. Psicofarmaci e anziani in: Gli psicofarmaci nella pratica terapeutica .Bellantuono, C. &
Tansella M. (Eds ) Il Pensiero Scientifico Editore Roma pp. 569-630 (1993) 9. Tagliavini, F., Angeretti, N., Chiesa, R. ,Verga, L., Salmona, M., Bugiani, O. and
Forloni, G. A prion protein peptide induces neuronal death by apoptosis in vitro in: Amyloid and Amyloidosis 1993 Kiselevsky, R. Benson, M. D., Frangione B., Gauldier J; Muckle T. J. and Young, I .D. (eds) Parthenon New York pp. 368-70 (1994).
10. Spagnoli, A., Forloni, G. and Lucca U. Farmaci antidemenza in: Principi di Farmacologia e terapia geriatrica. R. Rizzi (Ed)
Casa Editrice Ambrosiana. Milano, pp: 181- 227 (1994).
Forloni CV 22/10/2014
33
11. Forloni G. La proteina amiloide e la demenza di Alzheimer in: Il cervello senile S. Algeri (Ed)
Pythagora Press , Roma, pp. 203-219 (1995) 12. Tagliavini, F., Prelli, F., Giaccone, G., Forloni,G., Salmona, M., Picardo, P. Ghetti, B.,
Frangione, B. Bugiani, O. Methods for studyng prion protein amyloids in Methods in Molecular Medicine: Prion disease. Baker, C. and Ridley, S. (eds) Humana Press Inc. pp. 265-284 (1996)
13. Tagliavini, F., Prelli, F., Salmona, M., Ghetti, B., Giaccone, G., Bugiani, O., Frangione,
B. Forloni,G. Chemicophysical properties and biological activities of synthetic PrP peptides and their relation to the human cerebral PrP amyloidoses Transmissible subacute spongiform encephalopathies prion diseases Court, L. Dodert, B. (Eds.) Elsevier, pp. 323-327 (1997).
14. Tagliavini, F., Prelli, F., Salmona, M., Giaccone, G., Schettini, G., Ghetti, B., Bugiani,
O., Frangione, B. Forloni,G., PrP peptides and pathogenesis of prion diseases IN: Alzheimer's Disease: Biology, Diagnosis and Therapeutics Ikbal, K., Wimblad, B.,
Nishimura, T., Takeda, M. and Wisniewski , HM. (Eds) John Wiley & Sons (1997) 15. Tagliavini, F.,Giaccone, G., Prelli, F., Frangione, B., Salmona, M., Forloni,G., Ghetti,
B., Bugiani, O. PrP peptides as a tool to investigate the pathogenesis of prion protein amyloidoses In: Prions and brain diseases in Animals and Humans Morrison (Ed) Plenum Press New York (1998)
16 Tagliavini, F., Salmona, M., Forloni,G., Malesani, P., Giaccone, G., Canciani, B.,
MacArthur, R., Lansen, J. Piccardo, P., Dlouhy, SR., Ghetti, B., Frangione, B., Prelli, F.,Bugiani, O. Prion diseases: PrP peptides, pathogenesis and treatment perspectives
in : Prions: Molecular and cellular biology Harris DA (Ed) Horizon Scientific Press pp. 125-138 (1998)
17. Ruggieri, RM., Palermo, R., Calanni, P., Forloni, G., Lucca, U., Greco, E. and
Piccoli,F.Apolipoproteina E in un gruppo di pazienti siciliani affetti da malattia di Alzheimer In Atti XXVI Riunione LIMPE (1999)
18. Forloni, G., Galbete J. Angeretti N. -amiloide: i meccanismi della neurodegenerazione in Recenti progressi nella malattia di Alzheimer. Müller E. (Ed.)
Pythagora Press, Roma pp. 3-15 (2000) 19. Forloni, G. Malattie neurodegenerative e modelli sperimentali: quali prospettive? In:
VI Simposio AISAL . Malattie neurodegenerative, modelli sperimentali e loro prospettive. Bertorelli R., Costa, P., Forloni, G. Martino PA. (Eds) Milano AISAL pp. VI-X.
20. Awan T., Forloni, G, Ragg E., Iussich, S. Rossi G., Colombo L., Girola L. Massignan
T., Bugiani O., Salmona M., Tagliavini. F.Therapeutic approaches to prion diseases: in vitro studies with tetracycline compounds In: Alzheimer's Disease: : Advances in Etiology, Pathogenesis and Therapeutics Ikbal, K., Sisodia, S . and Wimblad, B. (Eds) John Wiley & Sons pp. 809-820 (2001)
Forloni CV 22/10/2014
34
21. Bertoli, A., Bertani I., Invernizzi, R. Forloni, G. � synuclein and dopaminergic degeneration in Parkinson's disease In: Research Advanced in Neurochemistry edit by Global Research Network (2000) 1: 83-103
22. Forloni G. Basi Biologiche delle sinucleinopatie In: Atti XXIX Riunione LIMPE (2002)
p. 96-107 23. Tagliavini F., Vari, MR., Limido R., Colombo, L., Rossi G., De Luigi, A. Morbin, M.
Gorla, G., Giaccone, G. Forloni, G. and Salmona, M. Tetracyclines for the treatment of prion diseases. In: Therapeutic Perspectives in TSE Lehmann S., Dormont, D., Gabizon, R. and Tagliavini (Eds)
24. Forloni G. I markers biologici nella Malattia di Alzheimer Syllabus, Neurological
Sciences Supplement (2004) 24: S702-S705 25. Chiesa, R., Fioriti, L, Tagliavini, F., Salmona M. and Forloni, G. Cytotoxicity of prion
peptides In Methods and Tools in Biosciences and Medicine: Techniques in Prion Research. Lehmann, S. & Grassi P. (eds) (2004 ) pp176-197
26. Giaccone G., Salmona, M. Tagliavini, F., Forloni, G. Brain dysfunction associated
with amyloid fibrils and other aggregated proteins. In: Amyloid proteins: The beta sheet conformation and disease Sipe J. (ed) 2005 by Wiley-VCH pp-355-377
27. Forloni G. Biologia dell'invecchiamento, Caleidoscopio Italiano (2005); n. 189: 72-98 28. Forloni G. Vaccino per l’Alzheimer realtà e speranze in Geriatria Ospedaliera (2006) 29. Albani D, Polito L, Vittori A, Forloni G Fattori di rischio genetici per le demenze e
screening per la loro indentificazione pre-clinica Ricerca & Pratica n.137: 204-211 (2007)
30. Forloni G. Ricerca traslazionale o semplicemente razionale, la ricerca per la malattia
di Alzheimer, Ricerca & Pratica n.173: 282-289 (2010)
31. Forloni G., Polito L., Davin A., Abbondanza S. ,Vaccaro R., Valle E., Guaita A., Colombo M., Vitali S., Ferretti V.V., Villani S. Cognitive stimulation and APOE genotype in non-demented elderly subjects: a randomized controller study (RCT). JHNA (The Journal of Nutrition, Health & Aging) 16: 841-2, (2012)
32. Guaita A., Abbondanza S., Colombo M., Davin A., Forloni G., Polito L., Vaccaro R., Valle E., Vitali S., Ferretti V.V., Villani S. Cognitive impairment, dementia and “good perfomers”: prevalence in the population study “InveCe.Ab”. JHNA (The Journal of Nutrition, Health & Aging) 16: 827-8, (2012 )
